Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02791308 · ClinicalTrials.gov registry record · Phase 3
Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis
A Phase 3 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 3
- Development phase
- 587
- Enrollment target
NCT02791308 is a Phase 3 study that has completed, run by Actavis. The registered enrollment target is 587 participants.
The verdict
NCT02791308, a Phase 3 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 587 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy profiles of Watson Laboratories, Inc.'s Pimecrolimus Cream, 1% to those of Valeant Pharmaceuticals North America LLC's Elidel® (pimecrolimus) Cream, 1%, and to demonstrate the superior efficacy of the two active creams over that of the placebo (Vehicle of test product), in the treatment of mild to moderate atopic dermatitis.
Interventions
- DRUG Vehicle cream
- DRUG Pimecrolimus Cream, 1%
- DRUG Pimecrolimus Cream 1% (Valeant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 587 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02791308
The ClinicalTrials.gov registry entry for NCT02791308 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 587 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle cream is the first listed.
NCT02791308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02791308 about?
NCT02791308 is a clinical study titled "Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis". The purpose of this study is to compare the safety and efficacy profiles of Watson Laboratories, Inc.'s Pimecrolimus Cream, 1% to those of Valeant Pharmaceuticals North America LLC's Elidel® (pimecrolimus) Cream, 1%, and to demonstrate the superior efficacy of the two active creams over that of the ...
What is the current status of trial NCT02791308?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 587 participants. The study started on 2015-02. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02791308?
The interventions under investigation include: Vehicle cream (DRUG), Pimecrolimus Cream, 1% (DRUG), Pimecrolimus Cream 1% (Valeant) (DRUG).
Who is sponsoring clinical trial NCT02791308?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.